5-hydroxytryptamine 2B Receptor Antagonism with MARY1 Attenuates Maladaptive Repair and Fibrosis Following Ischemic Kidney Injury

Mitochondrial dysfunction, persistent inflammation, maladaptive tubular repair and tubulointerstitial fibrosis are major causative factors that contribute to the onset and progression of acute kidney disease (AKD) and chronic kidney disease (CKD). Here, we investigate the therapeutic potential of MARY1, a novel, potent, and selective 5-hydroxytryptamine 2B (5-HT 2B ) receptor antagonist, on multiple key hallmarks known to drive the AKI-to-AKD transition. A mouse model of bilateral ischemia/reperfusion-induced renal injury was used to determine the therapeutic potential of MARY1 in vivo. Primary rabbit renal proximal tubule cells (RPTCs) were used to evaluate the cellular signaling effects of MARY1. Daily administration of MARY1 for 30 days (0.3 mg/kg, i.p.) post-injury restored renal function and mitochondrial biogenesis/dynamics. MARY1 also suppressed epithelial–mesenchymal and endothelial–mesenchymal transition (VE-cadherin, vimentin, FSP1, MMP-9), and reduced renal fibrosis (TGF-β, COL1A1, α-SMA). Furthermore, MARY1 attenuated inflammation as evidenced by downregulated NF-κB signaling and proinflammatory chemokine CXCL10, and augmented anti-inflammatory cytokines IL-9, IL-10, and IL-13. Importantly, MARY1 reduced p53 and p21 expression, indicating alleviated cell-cycle arrest. MARY1 also upregulated genes associated with successful proximal tubule cell repair (ACSM2A), while suppressing genes linked to failed repair (VCAM1 and PDGFRβ). These findings identify MARY1 as a novel, potent and selective 5-HT 2B receptor antagonist that restores mitochondrial homeostasis, promotes adaptive tubular repair, and prevents renal fibrosis following renal injury, thereby alleviating early AKD-to-AKD transition. This work highlights 5-HT 2B receptor antagonism and MARY1 as a promising therapeutic strategy to improve renal function and early recovery after ischemic injury.

Authors

Institutions

Publication Details

Journal
American Journal of Physiology-Renal Physiology
Published
2026-11-19
DOI
https://doi.org/10.1152/ajprenal.90077.2026
Primary Topic
Acute Kidney Injury Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

5-hydroxytryptamine 2B Receptor Antagonism with MARY1 Attenuates Maladaptive Repair and Fibrosis Following Ischemic Kidney Injury

Kristian P. Doyle, Rick G. Schnellmann, Jaroslav Janda, Paul Victor Santiago Raj et al.
American Journal of Physiology-Renal Physiology
Acute Kidney Injury Research
article

5-hydroxytryptamine 2B Receptor Antagonism with MARY1 Attenuates Maladaptive Repair and Fibrosis Following Ischemic Kidney Injury

Kristian P. Doyle, Rick G. Schnellmann, Jaroslav Janda, Paul Victor Santiago Raj, Jennifer Beischel Frye, Ishika Girdhar
article en

Abstract

Mitochondrial dysfunction, persistent inflammation, maladaptive tubular repair and tubulointerstitial fibrosis are major causative factors that contribute to the onset and progression of acute kidney disease (AKD) and chronic kidney disease (CKD). Here, we investigate the therapeutic potential of MARY1, a novel, potent, and selective 5-hydroxytryptamine 2B (5-HT 2B ) receptor antagonist, on multiple key hallmarks known to drive the AKI-to-AKD transition. A mouse model of bilateral ischemia/reperfusion-induced renal injury was used to determine the therapeutic potential of MARY1 in vivo. Primary rabbit renal proximal tubule cells (RPTCs) were used to evaluate the cellular signaling effects of MARY1. Daily administration of MARY1 for 30 days (0.3 mg/kg, i.p.) post-injury restored renal function and mitochondrial biogenesis/dynamics. MARY1 also suppressed epithelial–mesenchymal and endothelial–mesenchymal transition (VE-cadherin, vimentin, FSP1, MMP-9), and reduced renal fibrosis (TGF-β, COL1A1, α-SMA). Furthermore, MARY1 attenuated inflammation as evidenced by downregulated NF-κB signaling and proinflammatory chemokine CXCL10, and augmented anti-inflammatory cytokines IL-9, IL-10, and IL-13. Importantly, MARY1 reduced p53 and p21 expression, indicating alleviated cell-cycle arrest. MARY1 also upregulated genes associated with successful proximal tubule cell repair (ACSM2A), while suppressing genes linked to failed repair (VCAM1 and PDGFRβ). These findings identify MARY1 as a novel, potent and selective 5-HT 2B receptor antagonist that restores mitochondrial homeostasis, promotes adaptive tubular repair, and prevents renal fibrosis following renal injury, thereby alleviating early AKD-to-AKD transition. This work highlights 5-HT 2B receptor antagonism and MARY1 as a promising therapeutic strategy to improve renal function and early recovery after ischemic injury.

American Journal of Physiology-Renal Physiology
University of Arizona (US), Southern Arizona VA Health Care System (US)
Acute Kidney Injury Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon